A new analysis examined biological and ecological implications of targeted protein degradation technologies as they move toward therapeutic and research use. The work synthesizes evidence that selectively degrading proteins can produce off‑target physiological effects across species and urges more comprehensive safety evaluations. Authors call for standardized assays to assess systemic impacts and cross‑species toxicology, particularly for degrader modalities with irreversible biological consequences. Developers should incorporate these recommendations into preclinical pipelines and regulatory discussions.